Full-Time

Senior Manager Device Supplier Assurance

Confirmed live in the last 24 hours

Viatris

Viatris

10,001+ employees

No salary listed

Senior

Dublin, Ireland

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Degree in Engineering/Biomedical Science, Engineering or equivalent, with relevant experience within a medical device supplier lead role.
  • Experience within a medical devices and container closure systems environment with emphasis on drug delivery technologies would be a distinct advantage.
  • Experience of supplier evaluation & selection against technical need.
  • Excellent technical report writing skills.
  • Sound problem solving abilities.
  • Excellent communicator: clear and concise in communications with External and Internal partners with the ability to work flexibly across a multi-disciplinary team in jointly achieving departmental goals and established timelines.
  • Willingness to travel as necessary between the Global Device Development Teams & supplier.
  • Proficiency in speaking, comprehending, reading and writing English is required.
  • Attention to detail in all aspects of supplier management and a systematic approach to tasks.
Responsibilities
  • Responsibility for the generation and management of Supplier Control SOPs aligned with ISO13485, 21 CFR 820 and 21 CFR part 4 compliance, with emphasis on supplier selection, evaluation, & management.
  • Conduct supplier technical assessments identified as technical capability for potential business opportunities.
  • Responsible for the generation of Quality Technical Agreements and contractual agreements for CMO’s and service providers, along with maintenance of MSA’s and CDA’s.
  • Maintain a supplier technical assessment schedule and approved supplier list against business needs.
  • Primary contact for communications, escalation and resolution of supplier related quality and technical issues that may impact program timelines or contractual obligations.
  • Support the generation of projects, purchasing/supplier specifications.
  • Establish a supplier data base against cost, experience, & performance.
  • Building solid relationships within, Device Development, Device Compliance, Program Management, Legal, Finance, & external Viatris QA, CMO’s and service providers.
  • Proactively contribute through ownership of the deliverables of the Quality Objectives defined within the GDD QMS.
  • Monitor and provide supplier performance trending data for input to GDD Management Reviews.
  • Manage & execute supplier related change controls and supplier complaints for GDD.
  • Supervision within the Supplier Management group.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • DOJ's clearance of Mylan improves Viatris' public image and reduces legal uncertainties.
  • Consistent dividend policy for five years reflects Viatris' financial stability.
  • Participation in major healthcare conferences boosts Viatris' investor engagement.

What critics are saying

  • Increased competition from biosimilars threatens Viatris' market share.
  • Expiration of key drug patents in 2025 may lead to revenue loss.
  • Reliance on international markets exposes Viatris to geopolitical risks.

What makes Viatris unique

  • Viatris bridges the gap between generics and branded drugs globally.
  • Exclusive licensing with Lexicon enhances Viatris' cardiovascular portfolio outside U.S. and Europe.
  • Viatris' commitment to innovation is evident in its cenerimod research for lupus treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 3rd, 2025
Viatris To Report Fourth Quarter And Full Year 2024 Financial Results On February 27, 2025

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc

PR Newswire
Oct 16th, 2024
Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases. Leverages Viatris' Unique Global Infrastructure and Expertise. Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets outside of the United States and Europe